BioMarin Reports Record Financial Results for the First Quarter 2024

First Quarter 2024 Total Revenues of $649 Million (+9% Y/Y and +13% at Constant Currency Y/Y); GAAP Diluted Earnings per Share (EPS) of ...

First Quarter 2024 Total Revenues of $649 Million (+9% Y/Y and +13% at Constant Currency Y/Y); GAAP Diluted Earnings per Share (EPS) of ...

Quarterly Results - BioMarin Pharmaceutical Inc. - Financials

News - BioMarin Pharmaceutical Inc. - Investor Relations

April 24, 2024. BioMarin Reports Record Financial Results for the First Quarter 2024 · Read More. April 10, 2024. BioMarin to Host First Quarter 2024 Financial ...

BioMarin Pharmaceutical Inc. - Investor Relations

BioMarin to Host Third Quarter 2024 Financial Results Conference Call and ... Latest Quarterly Reports. Press Release · Presentation · Webcast · Form 10-Q · VIEW ...

BioMarin Reports Record Financial Results for the Fourth Quarter ...

Total FY'23 Revenues of $2.42 Billion (+15% Y/Y and +20% Y/Y at Constant Currency); GAAP Diluted Earnings per Share of $0.87 (+16% Y/Y) and ...

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third ...

Financial Highlights: Total Revenues for the third quarter of 2024 were $746 million, an increase of 28%, compared to the same period in 2023, ...

BioMarin Announces 20% Y/Y Total Revenue Growth in the Second ...

Second Quarter 2024 Total Revenues of $712 million (+20% Y/Y and +25% at Constant Currency Y/Y); First Half 2024 Total Revenues of $1.36 ...

BioMarin Reports Record Financial Results for the Fourth Quarter ...

"Strong financial results in 2023 were driven by global demand for VOXZOGO, the only approved treatment for children with achondroplasia, and ...

BioMarin Announces Record Breaking First Quarter 2023 Results ...

SAN RAFAEL, Calif. , April 26, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (BioMarin or the Company) today announced financial results for ...

AbbVie Reports First-Quarter 2024 Financial Results

AbbVie is raising its adjusted diluted EPS guidance for the full year 2024 from $10.97 - $11.17 to $11.13 - $11.33, which includes an unfavorable impact of $0. ...

BioMarin Reports Record Financial Results for the First Quarter ...

BioMarin Reports Record Financial Results for the First Quarter 2024 — programs discontinued · Comments Section · Community Info Section · More ...

Q1 2024 Biomarin Pharmaceutical Inc Earnings Call - Yahoo Finance

Results may differ materially depending on the progress of BioMarin's product programs, actions of regulatory authorities, availability of ...

BioMarin Pharmaceutical Stock News (BMRN) - Page 3 - Public.com

BioMarin Reports Record Financial Results for the First Quarter 2024. PRNewsWire • 04/24/24. Is a Surprise Coming for BioMarin (BMRN) This Earnings Season?

BioMarin to Host Second Quarter 2024 Financial Results ...

SAN RAFAEL, Calif., July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, ...

BMRN / BioMarin Pharmaceutical Inc. - SEC Filings, Annual Report ...

(415) 455-7558 (415) 455-7451 BioMarin Announces First Quarter 2019 Financial Results - Total Revenues Top $400 million in the Quarter - Full-year 2019 Total ...

BioMarin Announces Record Revenues in First Quarter 2022

"We begin 2022 from a position of financial strength including significant contributions from our newest product, Voxzogo, the only approved therapy for ...

All News for BMRN : BioMarin Pharmaceutical - Zacks.com

BioMarin: Q1 Earnings Snapshot. 04/24/24-4:14PM EST Associated Press, The. BioMarin Reports Record Financial Results for the First Quarter 2024. 04/24/24-4 ...

Hung Trinh posted on the topic | LinkedIn

That is impressive performance BioMarin Pharmaceutical Inc. BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and ...

bmrn-20221231 - SEC.gov

BIOMARIN PHARMACEUTICAL INC. 2022 FORM 10-K ANNUAL REPORT. TABLE OF CONTENTS ...